Cargando…
Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections – A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial
Background: Experience in treating human coronavirus (HCoV) infections might help to identify effective compounds against novel coronaviruses. We therefore performed a secondary subgroup-analysis of data from an open-label, uncontrolled clinical trial published in 2015 investigating the proanthocyan...
Autores principales: | Keck, Tilman, Strobl, Andreas, Weinhaeusel, Andreas, Funk, Petra, Michaelis, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120433/ https://www.ncbi.nlm.nih.gov/pubmed/33995094 http://dx.doi.org/10.3389/fphar.2021.666546 |
Ejemplares similares
-
Safety of Pelargonium extract EPs 7630 in young children with acute bronchitis
por: Kamin, Wolfgang, et al.
Publicado: (2023) -
Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells
por: Papies, Jan, et al.
Publicado: (2021) -
Corrigendum: Antiviral and Immunomodulatory Effects of Pelargonium sidoides DC. Root Extract EPs(®) 7630 in SARS-CoV-2-Infected Human Lung Cells
por: Papies, Jan, et al.
Publicado: (2021) -
Investigation of the influence of EPs(®) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses
por: Michaelis, Martin, et al.
Publicado: (2011) -
Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs(®) 7630) in the Context of Health Promotion
por: Kolodziej, Herbert
Publicado: (2011)